Madrigal Pharmaceuticals
Healthcare & Life Sci
Company overview
Madrigal Pharmaceuticals is a biopharmaceutical company that develops treatments for metabolic dysfunction-associated steatohepatitis, a liver disease known as MASH. Its lead product, Rezdiffra, is the first FDA-approved treatment for the condition. The company was founded in 2008 by Dr. Rebecca Taub.
Madrigal went public on NASDAQ in 2016 under the ticker MDGL. It started as a small team of researchers in Conshohocken, Pennsylvania and has grown into a fully integrated biopharmaceutical organization with hundreds of employees. Historically, the median salary is ~$228,013. Madrigal Pharmaceuticals is an H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- United States